5.39
Aldeyra Therapeutics Inc stock is traded at $5.39, with a volume of 660.92K.
It is down -3.06% in the last 24 hours and up +0.56% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$5.56
Open:
$5.56
24h Volume:
660.92K
Relative Volume:
0.65
Market Cap:
$322.84M
Revenue:
-
Net Income/Loss:
$-44.80M
P/E Ratio:
-7.1867
EPS:
-0.75
Net Cash Flow:
$-30.67M
1W Performance:
-3.06%
1M Performance:
+0.56%
6M Performance:
-22.78%
1Y Performance:
-12.92%
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ALDX
Aldeyra Therapeutics Inc
|
5.39 | 332.65M | 0 | -44.80M | -30.67M | -0.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
Apr-02-24 | Resumed | H.C. Wainwright | Buy |
Apr-27-22 | Resumed | H.C. Wainwright | Buy |
Feb-08-21 | Initiated | H.C. Wainwright | Buy |
Dec-16-20 | Initiated | Berenberg | Buy |
Oct-30-20 | Initiated | Jefferies | Buy |
Oct-16-20 | Initiated | BTIG Research | Buy |
Sep-22-20 | Initiated | Alliance Global Partners | Buy |
May-12-20 | Initiated | Oppenheimer | Outperform |
Dec-04-18 | Initiated | Citigroup | Buy |
Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
Sep-13-18 | Initiated | Janney | Buy |
Jan-26-18 | Initiated | Seaport Global Securities | Buy |
Sep-26-16 | Initiated | H.C. Wainwright | Buy |
Jul-01-16 | Initiated | Stifel | Buy |
Jul-01-15 | Initiated | Canaccord Genuity | Buy |
Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
Nov-18-14 | Initiated | H.C. Wainwright | Buy |
Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Proliferative vitreoretinopathy Pipeline Analysis & Clinical Trials, 2025, DelveInsight | Aldeyra Therapeutics, Tetra Bio-Pharma, Aviceda Therapeutics - The Globe and Mail
Published on: 2025-09-08 19:00:28 - beatles.ru
Is Aldeyra Therapeutics Inc. benefiting from interest rate changesWeekly Profit Analysis & Short-Term High Return Ideas - beatles.ru
ADAR1 Capital Management LLC Has $1.22 Million Position in Aldeyra Therapeutics, Inc. $ALDX - MarketBeat
Advanced analytics toolkit walkthrough for Aldeyra Therapeutics Inc.Market Activity Report & Low Risk Growth Stock Ideas - Newser
How to integrate Aldeyra Therapeutics Inc. into portfolio analysis toolsWeekly Loss Report & Community Driven Trade Alerts - Newser
Is Aldeyra Therapeutics Inc. a candidate for recovery play2025 Analyst Calls & Weekly Top Gainers Alerts - Newser
Earnings Recap: What is the long term forecast for Aldeyra Therapeutics Inc. stock2025 Risk Factors & Daily Volume Surge Signals - خودرو بانک
Wellington Management Group LLP Invests $675,000 in Aldeyra Therapeutics, Inc. $ALDX - MarketBeat
Momentum divergence signals in Aldeyra Therapeutics Inc. chartQuarterly Profit Report & Weekly High Conviction Ideas - Newser
Will Aldeyra Therapeutics Inc. outperform the marketJuly 2025 EndofMonth & Real-Time Volume Triggers - Newser
Does Aldeyra Therapeutics Inc. have strong fundamentalsCPI Data & AI Based Buy and Sell Signals - خودرو بانک
News impact scoring models applied to Aldeyra Therapeutics Inc.2025 Earnings Impact & Daily Market Momentum Tracking - Newser
Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis - MarketBeat
Sector ETF performance correlation with Aldeyra Therapeutics Inc.Market Risk Analysis & Consistent Profit Trading Strategies - Newser
Historical volatility pattern of Aldeyra Therapeutics Inc. visualizedQuarterly Market Review & High Return Trade Opportunity Guides - Newser
What technical models suggest about Aldeyra Therapeutics Inc.’s comebackWeekly Profit Report & Daily Chart Pattern Signals - Newser
Best data tools to analyze Aldeyra Therapeutics Inc. stock2025 Analyst Calls & Low Risk High Reward Ideas - Newser
How moving averages guide Aldeyra Therapeutics Inc. tradingRisk Management & Precise Buy Zone Tips - Newser
Is Aldeyra Therapeutics Inc. building a consolidation baseMarket Performance Report & AI Based Trade Execution Alerts - Newser
Can trapped investors hope for a rebound in Aldeyra Therapeutics Inc.Oil Prices & High Yield Stock Recommendations - Newser
Aldeyra granted fast track designation for ADX-2191 by FDA - MSN
Market reaction to Aldeyra Therapeutics Inc.’s recent newsMarket Movement Recap & AI Based Buy and Sell Signals - Newser
Can Aldeyra Therapeutics Inc. deliver consistent dividendsJuly 2025 Momentum & AI Based Buy and Sell Signals - خودرو بانک
Comparing Aldeyra Therapeutics Inc. in custom built stock radars2025 Retail Activity & Free Weekly Chart Analysis and Trade Guides - Newser
Using economic indicators to assess Aldeyra Therapeutics Inc. potentialWeekly Trade Recap & Reliable Breakout Stock Forecasts - Newser
Is Aldeyra Therapeutics Inc. stock bottoming outAnalyst Downgrade & Expert Curated Trade Ideas - Newser
Kingdon Capital Management L.L.C. Takes $4.48 Million Position in Aldeyra Therapeutics, Inc. $ALDX - MarketBeat
Full technical analysis of Aldeyra Therapeutics Inc. stockBear Alert & Detailed Earnings Play Strategies - Newser
Aldeyra Therapeutics Inc. stock trendline breakdownEarnings Miss & High Conviction Buy Zone Alerts - Newser
Can Aldeyra Therapeutics Inc. generate free cash flowInsider Buying & Community Verified Trade Signals - خودرو بانک
Using fundamentals and technicals on Aldeyra Therapeutics Inc.Portfolio Performance Summary & Long-Term Capital Growth Ideas - Newser
Aldeyra Therapeutics: A High-Potential Biotech Play in Immune-Mediated and Ophthalmic Diseases - AInvest
Tech Rally: Is Aldeyra Therapeutics Inc. stock forming a cup and handleTrade Risk Summary & High Return Stock Watch Alerts - خودرو بانک
Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
Real time scanner hits for Aldeyra Therapeutics Inc. explainedBreakout Watch & Daily Stock Trend Watchlist - Newser
Ranking Aldeyra Therapeutics Inc. among high performing stocks via tools2025 Price Momentum & Risk Managed Trade Strategies - Newser
Can Aldeyra Therapeutics Inc. expand its profit margins2025 Earnings Impact & Free High Return Stock Watch Alerts - خودرو بانک
Earnings visualization tools for Aldeyra Therapeutics Inc.Market Performance Report & Long-Term Capital Growth Ideas - Newser
What dividend growth rate does Aldeyra Therapeutics Inc. offer2025 Investor Takeaways & Technical Pattern Alert System - خودرو بانک
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):